• 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • br There are a few limitations to this study


    There are a few limitations to this study that should be mentioned. First, the prognostic information of patients with breast cancer with KMT2C mutations is absent for the Chinese cohort. Second, we identi-fied several significant differences between the Chinese, TCGA, and METABRIC cohorts, such as higher prevalence for KMT2C mutation in the Chinese ILC group, but the limited sample size hindered the ability to achieve a robust comparison among the three cohorts. Therefore, as
    Table 5
    Univariate and multivariate cox proportional hazards analysis of overall sur-vival for breast cancer patients in TCGA cohort.
    Univariate analysis
    Multivariate analysis
    Menopausal status 1
    Tumor size, cm 1
    Metastasis 1 1
    Histologic Subtype 1
    PR status 1
    HER2 status 1
    HRb status 1
    HR/HER2 subtype 1
    PIK3CA 1
    CI, confidence interval; KMT2C, Lysine Methyltransferase 2C; HR.
    a hazards ratio; HR. b Hormone receptor; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-ki-nase catalytic subunit alpha; TP53, tumor protein p53.
    one of the promising therapeutic targets for tumors, identifying the clinical value of KMT2C is still a long-term and arduous task, which requires further studies on the mechanism of KMT2C in breast cancer to provide a theoretical basis for KMT2C as an effective target for cancer therapy.
    Author’s contribution
    N Liao contributed to concept and design of this article, X Chen,G Zhang, B Chen participated in manuscript writing. N Liao, X Chen, G Zhang, B Chen, L Guo, Li Cao, C Ren, L Wen participated in sample collection, sample processing, clinical information collection and data  Biomedicine & Pharmacotherapy 116 (2019) 108997
    analysis. N Liao, X Chen,G Zhang, B Chen analyzed and interpreted data. All authors read and approved the final manuscript.
    Conflict of interest
    The authors declare no competing financial interests.
    Acknowledgments and Funding
    A.H. Ramos, R. Rebollar-Vega, S. Rodriguez-Cuevas, S.L. Romero-Cordoba, S.E. Schumacher, N. Stransky, K.M. Thompson, L. Uribe-Figueroa, J. Baselga, R. Beroukhim, K. Polyak, D.C. Sgroi, A.L. Richardson, G. Jimenez-Sanchez,
    J. Robertson, J.M. Bliss, I. Smith, M. Dowsett, POETIC Trial Management Group and Trialists, Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation, Nat. Commun. 7 (2016) 13294.
    S.A. Martin, C. Chelala, F.R. Balkwill, J. Fitzgibbon, R.P. Grose, Reduced Melatonin of histone methyltransferases KMT2C and KMT2D correlates with improved out-come in pancreatic ductal adenocarcinoma, Cancer Res. 76 (16) (2016) 4861–4871.
    K. Raine, K. Ramakrishnan, F.G. Rodríguez-González, G. Romieu, A.M. Sieuwerts, P.T. Simpson, R. Shepherd, L. Stebbings, O.A. Stefansson, J. Teague, S. Tommasi, I. Treilleux, G.G. Van den Eynden, P. Vermeulen, A. Vincent-Salomon, L. Yates,
    9 Original Study
    Association Between Hospitals’ Risk-Adjusted Emergency Department Visits and Survival and Costs in Kidney Cancer Patients Undergoing Nephrectomy
    The study aimed to assess the relationship between a hospital’s risk-adjusted emergency department (ED) visit rate and its risk-adjusted mortality rate and costs among kidney cancer patients undergoing nephrectomy as initial treatment. Hospitals’ risk-adjusted 30-day ED rates were not significantly associated with risk-adjusted mortality or costs. Although risk-adjusted 365-day ED rates were associated with significantly higher costs. Purpose: To estimate the association between a hospital’s risk-adjusted emergency department (ED) visit rate and its risk-adjusted mortality rate and costs among kidney cancer patients undergoing initial nephrectomy. Patients and Methods: Using 2007-2012 Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we used logistic regression to model ED visit occurrence within 30 and 365 days for all kidney cancer patients receiving initial surgery. Our model controlled for demographics, stage, histology, systemic targeted therapy, and comorbidities. Based on model predictions, we created a ratio of actual versus predicted ED visits for hospitals to identify hospitals with higher and lower than predicted ED visit rates. We estimated the association between the hospitals’ ED visit ratio and hospitals’ risk-adjusted 365-day mortality rates, and 6- and 12-month total costs and total costs (less ED visits). Results: In our sample of 6078 patients, 15.5% had an ED visit within 30 days of surgery and 43.5% within 365 days. For hospitals with 11 patients, we found no statistically significant association between 30-day or 365-day risk-adjusted ED visit rate and their 365-day risk-adjusted mortality rate. Hospitals’ 30-day ED visit rates were not significantly associated with either 6- or 12-month costs. However, hospitals’ 365-day ED visit rates were significantly associated with 12-month costs, even when excluding the cost of the ED visit. Conclusion: Our results suggest hospitals’ risk-adjusted ED visit rates capture a qualitatively different measure of quality than the more commonly reported mortality rates. Longer term ED visit rates are cytokinins significantly associated with increased costs while 30-day ED visits are not.